Who Are the Core Customers in Pacira Company's Target Market?

Orthopedic surgeons performing total joint replacements and soft-tissue surgeons doing hernia and bariatric repairs are Pacira target customers because they drive procedure-led volume and routine EXPAREL use; joint-replacement pathways alone account for a material share of perioperative analgesic demand. See Ownership and Control of Pacira Company for corporate context: Ownership and Control of Pacira Company

Anesthesiologists and certified registered nurse anesthetists (CRNAs) select multimodal pain protocols and are key influencers in product adoption; they evaluate efficacy, workflow impact, and opioid-sparing outcomes when choosing Pacira products.

Hospital pharmacy directors, clinical administrators, and C-suite executives at hospitals and ambulatory surgery centers Pacira customers control formulary placement, contracting with group purchasing organizations, and decisions as surgical volume shifts outpatient.

The hospital acute-care channel – especially orthopedic joint-replacement programs and high-volume ASCs – appears most important by revenue and usage; institutional formulary wins translate to repeat orders and drive a large portion of Pacira customer profile for EXPAREL buyers.

Pacira target customers cluster in ASCs and HOPDs across the U.S.; outpatient migration means over 70% of elective orthopedic procedures now occur outside inpatient hospitals, increasing demand for nonopioid agents that shorten recovery time.

States with higher shares of residents aged 65+ and aggressive opioid stewardship – such as Florida, Arizona, and parts of the Southeast – show above-average uptake; hospitals and ambulatory surgery centers Pacira customers in these regions prioritize opioid-sparing protocols.

Orthopedic surgeons as Pacira target customers drive the largest share of usage – approximately 60% of EXPAREL utilization – making orthopedics the core revenue driver in Pacira customer profile for EXPAREL buyers within ASCs and HOPDs.

High-growth niches include sports medicine and pediatric surgery where parents and athletes seek to eliminate opioid exposure; these segments, plus continued outpatient migration, are the fastest-growing healthcare providers for Pacira products in 2025 – 2026.

Pacira expands its target customers by securing FDA approvals for higher-frequency procedures such as lower extremity nerve blocks, widening the Pacira target customers pool to include orthopedic and plastic surgeons plus ambulatory surgery centers. This increases the total addressable market and brings more hospitals and ambulatory surgery centers Pacira customers into play.

Retention hinges on educational partnerships, clinical evidence programs, and protocol embedding that make EXPAREL a standard of care for postoperative pain. Hospital pharmacy procurement processes and group purchasing organizations see clinical and operational value, keeping surgeons and anesthesiologists as repeat Pacira buyers.

Repeat demand is driven by clinical outcomes data and training that create ecosystem stickiness among anesthesiologists and pain management physicians. Targeted account management focuses on top-tier surgical accounts that generate 80 percent of procedural volume, deepening relationships with hospital pharmacy and clinical administrators.

The primary lever is the 2025 implementation of the NOPAIN Act, which creates a dedicated payment stream for non-opioids in outpatient settings and expands accessible patient population in 2026. Combined with a specialized sales force focused on top surgical accounts and ongoing indication expansion, Pacira aims for steady market share growth despite generic competition. Read more on strategy in Sales and Marketing Strategy of Pacira Company.